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DILI and the therapeutic action of IV NAC are both 
unknown, this case strongly implies at least some 
commonality. Because IV amiodarone is indicated for 
the treatment of serious cardiac arrhythmias in an 
intensive care unit setting, some degree of ischemic 
hepatitis is likely a cofactor in most cases. 
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Core tip: Intravenous (IV) amiodarone drug induced 
liver injury (DILI) is uncommon, and difficult to 
distinguish from ischemic hepatitis or congestive 
hepatopathy. Further, the pathophysiology is uncertain. 
IV N-acetylcysteine (NAC) is often used empirically as 
a treatment for idiopathic hepatitis or DILI. We report 
a case of rapid improvement of liver enzymes in a 
suspected case of IV amiodarone DILI with IV NAC, 
suggesting at least some shared features between 
the pathogenic mechanisms of the former and the 
therapeutic actions of the latter.
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INTRODUCTION
Intravenous (IV) amiodarone drug induced liver injury 
(DILI) is uncommon, and difficult to distinguish from 
ischemic hepatitis or congestive hepatopathy. Further, 
the pathophysiology is uncertain. IV N-acetylcysteine 
(NAC) is often used empirically as a treatment for 
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Abstract
We report a case of intravenous (IV) amiodarone 
drug induced liver injury (DILI). The patient received 
IV N-acetylcysteine (NAC) which resulted in a rapid 
improvement in liver enzymes. While the specific 
mechanisms for the pathogenesis of IV amiodarone 
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idiopathic hepatitis or DILI. We report a case of rapid 
improvement of liver enzymes in a suspected case of IV 
amiodarone DILI with IV NAC, suggesting at least some 
shared features between the pathogenic mechanisms of 
the former and the therapeutic actions of the latter.
CASE REPORT
A 65-year old woman presented to her primary 
physician with fatigue and shortness of breath. She 
was treated with ciprofloxacin and oral prednisone 
for presumptive upper respiratory tract infection and 
asthma, respectively. Five days later, her symptoms 
worsened. She presented to the emergency room, 
was found to be hypotensive and hypoxic, and 
was admitted to an intensive care unit. Aside from 
the asthma, her past medical history included 
hypothyroidism and remote breast cancer/mastectomy. 
There was no history of alcohol use and she was non-
obese.
On admission, chest X-ray revealed marked 
cardiomegaly and right lower lobe infiltrate and she 
was treated with antibiotics for community acquired 
pneumonia and presumed sepsis. Echocardiogram 
revealed severe global left ventricular dysfunction with 
ejection fraction 15%. The patient was hypotensive 
on presentation due to mixed septic and cardiogenic 
shock and required aggressive fluid resuscitation 
and intermittent pressor support. Lactate levels were 
elevated (2.5 mmol/L), as were alanine transaminase 
(ALT) and aspartate transaminase (AST) (439 U/L 
and 305 U/L, respectively). Lactate levels would 
later normalize and remain largely unremarkable. 
Transaminases remained elevated (ALT 602 U/L and 
AST 212 U/L) over the next 2 d.
On hospital day 4, the patient developed atrial 
fibrillation with rapid ventricular response which was 
poorly tolerated hemodynamically. She received 
a 150 mg bolus of amiodarone which resulted in 
worsening hypotension requiring pressor support, 
but with no other signs of drug reaction. No further 
amiodarone was given. Following this episode, there 
was an acute elevation of ALT to 1730 U/L and AST to 
1650 U/L, which was believed secondary to transient 
hypoperfusion. 
Over the next 12 d, liver enzymes spontaneously 
decreased to ALT and AST of 204 U/L and 56 U/L 
respectively. An evaluation including a viral hepatitis 
panel, anti-nuclear antibodies, smooth muscle 
antibody, serum electrophoresis, anti-liver kidney 
microsomal 1 and duplex ultrasound were negative. 
Cardiac catheterization revealed no significant 
obstructive coronary disease.
The patient’s respiratory and clinical status 
improved during this time. However, she remained in 
atrial fibrillation with rapid ventricular rates refractory 
to beta blockers and digoxin. On hospital day 17, 
after a transesophageal echocardiography guided 
cardioversion, the patient received a slow infusion 
of amiodarone (0.5 mg/min) without bolus during 
careful monitoring of her blood pressure. She received 
approximately 900 mg IV amiodarone overnight and 
no hypotension was observed. IV amiodarone was 
then stopped due to nausea, but another 3 doses of 
200 mg of oral amiodarone were administered the 
next day. In the next 5 d, her transaminases again 
rose quickly and significantly in a stepwise manner. On 
day 23, her ALT and AST were 1541 U/L and 3994 U/L. 
Aside from occasional low dose acetaminophen (APAP), 
total dose 3900 mg in a 48 h period between days 
18 and day 20, she was not on any other hepatotoxic 
medications. No acetaminophen was given after day 
20. A liver biopsy was not done.
IV NAC, 300 mg/kg, was then administered over 
21 h using the standard United States Food and Drug 
Administration approved acetaminophen protocol. 
After 12 h of NAC, her AST fell by 50% to 1958 U/L. 
Twenty-four hours later the AST fell to 851 U/L, 
representing an 80% decrease (Figure 1). 
Over the next 8 d, the liver enzymes continued 
to decrease and day 34 (day of death) ALT and AST 
were 84 U/Land 142 U/L. However, her bilirubin 
began to increase at hospital day 27, and direct and 
total bilirubin elevated to 11.75 mg/dL and 16.0 
mg/dL respectively after the second IV amiodarone 
administration. Concurrently, she had developed 
fungemia and died of multi organ failure. 
DISCUSSION
Acute IV amiodarone toxicity, in contrast to chronic 
oral use, is relatively rare[1]. Gluck et al[2] have recently 
even questioned its existence. However, a number 
of case reports have been described. Because IV 
amiodarone is often used in seriously ill patients for 
cardiac indications, it can be challenging to distinguish 
DILI from ischemic hepatitis from, for example, even 
transient hypotension or other co-morbid events. 
Moreover, as is the case in this report, liver histology 
is frequently not obtained, as these patients are 
sick and frequently are on anti-platelet agents or 
anticoagulation. Consistent with prior reports, IV 
amiodarone DILI, like ischemia, causes an acute and 
severe hepatitis. We believe IV amiodarone DILI is 
most likely in our case as there was no significant 
evidence for hypotension and there was a re-challenge. 
The etiology of IV amiodarone DILI is unknown, but 
is thought to be considerably different from the more 
common chronic oral hepatotoxicity. NAC is often used 
off-label for non-acetaminophen acute liver failure, 
including DILI in both adult and pediatric populations 
with mixed success[3,4]. 
We note in Figure 2[5-11] that there are (1) 
numerous putative non-exclusive mechanisms by 
which IV amiodarone might cause acute DILI; and 
(2) numerous putative non-exclusive mechanisms 
by which IV NAC might treat DILI[5]. However, 
recent elegant work by Serviddio et al[6] bridged 
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these terrains. Using a rat model, their research 
focused on the impact of mitochondrial oxidative 
stress and respiratory chain dysfunction as key 
to the pathogenesis of amiodarone hepatotoxicity 
and showed that NAC specifically abrogates these 
deleterious effects. In doing so, their work elucidates 
some of the basic mechanisms of both drugs, at least 
when co-administered. Although their research used a 
murine model, it served as the basis for the use NAC 
in this patient.
Our results, which show a striking improvement 
in transaminases levels immediately following NAC 
administration, are consistent with their experience. 
And while some reports of IV amiodarone DILI have 
described spontaneous resolution of hepatic injury, 
we believe this is the first describing improvement 
attributable to NAC. Using a cell culture model, 
Durukan et al[12] have also reported that NAC can treat 
amiodarone toxicity.
In retrospect, our patient may have benefited from 
additional NAC, as her transaminase improvement 
stalled somewhat after discontinuation. We used the 
standard 21 h APAP/NAC protocol, believing this to 
be adequate. However, others have reported using 
longer protocols for DILI and/or acute hepatotoxicity. 
Also, our patient received low dose acetaminophen as 
an anti-pyretic around the time she received the IV 
amiodarone. Although this was promptly discontinued 
as her transaminases were rising, it is possible even 
these low doses potentiated the IV amiodarone DILI 
and/or its apparent responsiveness to NAC. The patient 
ultimately died of multi-organ failure and fungemia; 
the contribution of her liver toxicity was uncertain but 
probably small. 
Finally, although she did not have any significant 
known hypotensive episodes around the time of 
her second amiodarone infusion, we cannot fully 
exclude the possibility that there could have been 
some contribution from ischemia. Indeed, the fact 
that her AST was higher than her ALT on her second 
flare, this may be likely[13]. Application of the Council 
for International Organizations of Medical Sciences 
scale for causality assessment is useful: our patient 
scores maximally in favor of DILI for each of the seven 
items of hepatocellular injury with the exception of 
possible recent hypotension and the interpretation of 
her second ALT response[14]. As such, she scores as 
either “highly probable” or only “probable”. We note, 
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Figure 1  Temporal relationship of amiodarone and N-acetylcysteine administration to transaminases. Most labs were drawn between 4 am and 6 am. NAC 
administration began during the afternoon of day 24. NAC: N-acetylcysteine; ALT: Alanine transaminase; AST: Aspartate transaminase; APAP: Acetaminophen.
Amiodarone
putative mechanisms of injury[6,7]
N-acetylcysteine
putative mechanisms of treatment[8-11]
1. Micro/macrovesicular steatosis
2. Oxidative stress/mitochondrial impairment
3. Tissue phospholipid injury
4. Other/combinations of 1-3
1. Increased mitochondrial and cytosolic glutathione production
2. Tissue oxygen delivery
3. Support mitochondrial energy metabolism
4. Increased hypotaurine concentrations
5. Decreased endothelial dysfunction
6. Other/combinations of 1-5
Figure 2  Possible mechanism of injury and treatment.
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however, that since IV amiodarone is indicated in the 
treatment of serious cardiac arrhythmias, ischemic 
hepatitis is a universal bedside consideration, which 
may lead to the under-diagnosis and under-reporting 
of IV amiodarone DILI.
Some authors have postulated that the diluent 
polysorbate 80 may be responsible for toxicity seen 
with IV but not oral amiodarone[15]. While our results 
do not disagree with this possibility, our apparent 
NAC responsiveness makes this seem unlikely in 
the present report. It is noted that while our IV 
amiodarone did contain polysorbate 80, IV amiodarone 
is commercially available without this diluent. 
In conclusion, we believe that NAC at least partially 
treated IV amiodarone DILI for our patient. This 
experience lends support to a shared mitochondrial 
dysfunction/oxidative stress mechanism for these 
drugs, with NAC specifically ameliorating the injury 
from amiodarone in this setting. Earlier and more 




Iintravenous (IV) amiodarone drug induced liver injury possibility treated with IV 
N-acetylcysteine (NAC).
Clinical diagnosis
Transaminases fell markedly after IV NAC administration
Differential diagnosis 
Ischemic hepatitis was a likely cofactor. 
Laboratory diagnosis 
Transaminases rose twice in response to IV amiodarone, but fell precipitously 
after IV NAC.
Treatment 
IV NAC was the only liver specific treatment applied.
Related reports 
Multiple other reports have described IV amiodarone toxicity, but its incidence, 
pathogenesis, and ideal treatments remain unknown.
Peer-review
This is an interesting case reports with various clinical issues. The manuscript 
is interesting and well written.
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